Literature DB >> 11719456

Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma.

M Höglund1, T Säll, S Heim, F Mitelman, N Mandahl, I Fadl-Elmula.   

Abstract

The clinical course in urinary bladder cancer is difficult or impossible to predict based on conventional disease parameters. It is a reasonable hypothesis that the genetic aberrations acquired by the tumor cells, being instrumental in bringing about the disease in the first place, may also hold the key to more reliable prognostication. However, though 200 transitional cell carcinomas (TCC), the most common bladder cancer in the Western world, with clonal chromosomal abnormalities have been reported, our knowledge about the karyotypic characteristics of these tumors remains insufficient. The aberration pattern is clearly nonrandom, but no completely specific primary or secondary karyotypic abnormality has been identified, and the chronological order in which the aberrations appear during disease progression is not well known. The high degree of karyotypic complexity in epithelial tumors like TCC is one reason why our picture of the sequential order of cytogenetic evolution is unclear. To overcome some of these difficulties we have used several statistical methods that allow analysis and interpretation of the relationship between cytogenetic aberrations in TCC. We show that there exists a temporal order with respect to the appearance of chromosomal imbalances and that this order is highly correlated with tumor stage and grade. Analyzing changes in the distribution of imbalances per tumor in G1, G2, and G3 tumors, we suggest that progression involves the acquisition of cytogenetically detectable and submicroscopic genetic changes at comparable frequencies. By means of computer simulations, we show that the imbalances -9, +7, and 1q+ appear earlier than expected from random events and that -6q, -5q, -18, +5p, -22p, and -15 appear later than expected. Using principal component analysis, we identify two cytogenetic pathways in TCC, one initiated by -9 and followed by -11p and 1q+, the other initiated by +7 and followed by 8p- and +8q. The -9 pathway was correlated with stage Ta-T2 tumors, whereas the +7 pathway was correlated with stage T1-T3 tumors, i.e., +7 tumors appeared to be more aggressive. Although these pathways are well separated at earlier stages, they later converge to contain a common set of imbalances.

Entities:  

Mesh:

Year:  2001        PMID: 11719456

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

Review 1.  Molecular biology of bladder cancer.

Authors:  William Martin-Doyle; David J Kwiatkowski
Journal:  Hematol Oncol Clin North Am       Date:  2015-01-31       Impact factor: 3.722

2.  MCL1 and DEDD Promote Urothelial Carcinoma Progression.

Authors:  Jonathan E Rosenberg; William C Hahn; Andrew L Hong; Jennifer L Guerriero; Mihir B Doshi; Bryan D Kynnap; Won Jun Kim; Anna C Schinzel; Rebecca Modiste; Amy J Schlauch; Rosalyn M Adam; David J Kwiatkowski; Rameen Beroukhim; Anthony Letai
Journal:  Mol Cancer Res       Date:  2019-02-18       Impact factor: 5.852

3.  Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.

Authors:  Rosário Pinto-Leite; Isabel Carreira; Joana Melo; Susana Isabel Ferreira; Ilda Ribeiro; Jaqueline Ferreira; Marco Filipe; Carina Bernardo; Regina Arantes-Rodrigues; Paula Oliveira; Lúcio Santos
Journal:  Tumour Biol       Date:  2014-01-24

4.  Specific aneusomies in Chinese hamster cells at different stages of neoplastic transformation, initiated by nitrosomethylurea.

Authors:  Alice Fabarius; Andreas Willer; George Yerganian; Ruediger Hehlmann; Peter Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

5.  Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.

Authors:  Markus Riester; Lillian Werner; Joaquim Bellmunt; Shamini Selvarajah; Elizabeth A Guancial; Barbara A Weir; Edward C Stack; Rachel S Park; Robert O'Brien; Fabio A B Schutz; Toni K Choueiri; Sabina Signoretti; Josep Lloreta; Luigi Marchionni; Enrique Gallardo; Federico Rojo; Denise I Garcia; Yvonne Chekaluk; David J Kwiatkowski; Bernard H Bochner; William C Hahn; Azra H Ligon; Justine A Barletta; Massimo Loda; David M Berman; Philip W Kantoff; Franziska Michor; Jonathan E Rosenberg
Journal:  Clin Cancer Res       Date:  2014-01-31       Impact factor: 12.531

Review 6.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

7.  Detailed Analysis of Focal Chromosome Arm 1q and 6p Amplifications in Urothelial Carcinoma Reveals Complex Genomic Events on 1q, and SOX4 as a Possible Auxiliary Target on 6p.

Authors:  Pontus Eriksson; Mattias Aine; Gottfrid Sjödahl; Johan Staaf; David Lindgren; Mattias Höglund
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

8.  Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma.

Authors:  David Lindgren; Gottfrid Sjödahl; Martin Lauss; Johan Staaf; Gunilla Chebil; Kristina Lövgren; Sigurdur Gudjonsson; Fredrik Liedberg; Oliver Patschan; Wiking Månsson; Mårten Fernö; Mattias Höglund
Journal:  PLoS One       Date:  2012-06-07       Impact factor: 3.240

9.  Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder.

Authors:  Zhongfa Zhang; Kyle A Furge; Ximing J Yang; Bin T Teh; Donna E Hansel
Journal:  BMC Med Genomics       Date:  2010-12-15       Impact factor: 3.063

10.  Chromosomal aberrations in bladder cancer: fresh versus formalin fixed paraffin embedded tissue and targeted FISH versus wide microarray-based CGH analysis.

Authors:  Elena Panzeri; Donatella Conconi; Laura Antolini; Serena Redaelli; Maria Grazia Valsecchi; Giorgio Bovo; Francesco Pallotti; Paolo Viganò; Guido Strada; Leda Dalprà; Angela Bentivegna
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.